MD PhD A. Wolkerstorfer

Medical Specialist
Main activities
Patient care, Research
Focus of research
Laserdermatology: clinical research on laser treatments; development of innovative treatments

Pigment disorders: clinical research, research on pigmentcell transplantation

Key publications
  • Kroon Marije W., Wind Bas S., Beek Johan F., van der Veen J. P. Wietze, Nieuweboer-Krobotová Ludmila, Bos Jan D., Wolkerstorfer Albert Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled pilot study Journal of the American Academy of Dermatology 2011;64 (3):516-523 [PubMed]
  • Wind Bas S., Kroon Marije W., Meesters Arne A., Beek Johan F., van der Veen J. P. Wietze, Nieuweboer-Krobotová Ludmila, Bos Jan D., Wolkerstorfer Albert Non-Ablative 1,550 nm Fractional Laser Therapy Versus Triple Topical Therapy for the Treatment of Melasma: A Randomized Controlled Split-Face Study Lasers in surgery and medicine 2010;42 (7):607-612 [PubMed]
  • Brenninkmeijer E. E. A., Spuls P. I., Lindeboom R., van der Wal A. C., Bos J. D., Wolkerstorfer A. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot British journal of dermatology 2010;163 (4):823-831 [PubMed]
  • van Drooge Anne Margreet, Beek Johan F., van der Veen J. P. Wietze, van der Horst Chantal M. A. M., Wolkerstorfer Albert Hypertrophy in port-wine stains: Prevalence and patient characteristics in a large patient cohort Journal of the American Academy of Dermatology 2012;67 (6):1214-1219 [PubMed]
  • Vrijman C., van Drooge A. M., Limpens J., Bos J. D., van der Veen J. P. W., Spuls P. I., Wolkerstorfer A. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review British journal of dermatology 2011;165 (5):934-942 [PubMed]
All Publications
Research programmes

Prof. PhD R.M. Luiten (Pigment cell disorders of the skin)

Luiten's research team is specialized in the immunopathogenesis and treatment of pigment cell disorders of the skin, including vitiligo and melanoma. Luiten's research has clearly established a positive relation between vitiligo and melanoma regression, by showing that 1) vitiligo patients have a three-fold decreased life-time risk of developing melanoma , 2) vitiligo is an autoimmunity against melanocytes in the skin, leading to loss of skin pigmentation, 3) melanoma patients who develop vitiligo, referred to as melanoma-associated leucoderma or vitiligo (MAL), have immunity reactive with both melanocytes and melanoma cells, 4) the appearance of MAL in melanoma patients is associated with favorable clinical outcome (progression free- and overall survival), and 5) vitiligo-inducing compound monobenzone combined with imiquimod and/or CpG induces anti-melanoma immunity and suppresses melanoma growth in mice and patients. This highlights vitiligo as a favorable sign for melanoma patients and the importance of its mechanism of action for melanoma treatment. The group has developed a new melanoma therapy consisting of monobenzone and immune stimulation (patent granted, preclinical and clinical proof-of-concept obtained). Their investigator-initiated clinical trial at the NKI-AVL shows local clinical responses of skin metastases and successful induction of anti-melanoma immunity in most patients. This therapy is developed further clinically. New projects include biomarker research for response of melanoma patients to immune checkpoint inhibitors, targeting of melanoma cell heterogeneity by vaccination immunotherapy and diagnosis and treatment of lentigo maligna. Vitiligo clinical research aims at improving skin suspension transplantation therapy and the development of  scoring systems for vitiligo disease activity. Biomarkers for the differential diagnosis of vitiligo and melanoma-associated vitiligo are studied, applicable in preventing immunesuppressive therapy in vitiligo patients with an undiagnosed melanoma. Luiten's group joined forces of the NFU expertise center on Pigment Disorders (AMC) with the skin tissue engineering expertise of prof Gibbs (VUMC), to apply this technology in vitiligo and melanoma immunotherapy research. 


PhD W.J. Bakker
MD PhD M.W. Bekkenk
MD PhD M.A. Middelkamp Hup
MD PhD A. Wolkerstorfer

PhD W. Ouwerkerk

BEng S. Chielie
BEng G. Krebbers
N.O.P. van Uden

Current research funding
  • AMC
  • Novartis Pharma AG